珍宝岛药业没有止步于传统中药业务，特别是随着近年来中医药获得全方位政策支持，国务院办公厅 2025年印发《关于提升中药质量促进中医药产业高质量发展的意见》，为中医药产业高质量发展提供了 政策支撑。国内中医药产业也正沿着高质量发展的轨道前行，中药领域的科技创新也展现出不俗的发展 动能。 今年，珍宝岛药业1.1类中药创新药清降和胃颗粒迎来关键节点，其Ⅱ期临床试验在长沙市第三医院实 现全国首例患者入组。该品种主要针对非糜烂性胃食管反流病（NERD）寒热错杂证这一西医治疗手段 匮乏的复杂证型，借助整体调节优势，有望填补中医证候治疗市场空白。Ⅱ期临床的启动，也标志着其 研发正式迈入验证有效性与安全性的成药性转化核心阶段，如果能够成功上市，按照现有规定，该品种 将享有市场独占期与价格优势。不仅将打开十亿级细分市场，也有望提升公司管线整体估值溢价。 另据东方财富Choice数据，由于上述Ⅱ期临床试验的启动，珍宝岛药业今年9月25日还新增"创新药"概 念，不难看出业界对该产品的认可。 生物药赛道投资进入价值兑现期 中药业务夯实基本盘，重磅品种清降和胃颗粒有望填补中医证候治疗空白，潜在市场超十亿元；数年前 就着手布局的生物药赛 ...

Market Overview - The A-share market saw all three major indices rise collectively, with the Shanghai Composite Index up by 0.14%, Shenzhen Component Index up by 1.61%, and ChiNext Index up by 2.76% as of the midday close [2] - The total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 1.1439 trillion yuan, a decrease of 39.2 billion yuan compared to the previous trading day [2] - Over 2,800 stocks in the market experienced gains [2] Sector Performance - The CPO sector continued to strengthen, with Longguang Huaxin hitting the daily limit [3] - The flu sector showed strong performance, with stocks like Yue Wannianqing and Huaren Health also hitting the daily limit, and Haiwang Biological experiencing a rapid surge to the limit within three minutes [3][4] - The pharmaceutical sector saw a collective explosion, driven by flu and innovative drug concepts, with several companies reaching the daily limit [4] Industry Catalysts - The arrival of the flu season has provided a strong catalyst for pharmaceutical stocks, with the China CDC reporting that flu activity is currently at a rising stage, particularly in southern provinces [6] - Companies like Zhenbaodao have responded to investor inquiries regarding their flu treatment drugs, which are currently in production and sale [7] - Shiyao Group announced that its self-developed siRNA drug has received FDA approval for clinical trials in the U.S. and is set to begin trials in China in 2025 [7] Macro Trends - According to Everbright Securities, the global economy is returning to a rate-cutting cycle, which is expected to benefit innovative assets [7] - The aging population globally is driving an increase in healthcare spending, expanding the global demand for pharmaceuticals [7] - China's pharmaceutical innovation is on the rise, with a growing share of the global pharmaceutical market expected to be captured by the Chinese industry [7] AI and Cloud Computing - The computing power hardware sector saw renewed activity, with stocks like Zhongji Xuchuang and Xinyi Sheng experiencing significant gains [8] - Alibaba Group reported a revenue of 247.795 billion yuan for Q2 of fiscal year 2026, exceeding market expectations with a year-on-year growth of 15% [9] - Alibaba's CEO highlighted the synergy between AI to B and AI to C strategies, which are expected to drive continued growth [9] - The AI cloud market in China is led by Alibaba Cloud, which is seen as a core driver of growth in cloud computing [9]

Group 1 - The company, Zhenbao Island, has indicated that it offers treatment drugs for both Type A and Type B influenza [1] - The products currently in production and on sale include injectable Yanhuning, compound Qilan oral solution, children's Resuqing syrup, Shuanghuanglian oral solution, Shuanghuanglian injection, and injectable Shuanghuanglian [1]

Group 1 - The company, Zhenbaodao (603567.SH), has confirmed that it produces and sells several treatment drugs for influenza A and B, including injectable Yanhuning, compound Qilan oral solution, children's Resuqing syrup, Shuanghuanglian oral solution, Shuanghuanglian injection, and injectable Shuanghuanglian [1]

Core Viewpoint - The 90th National Pharmaceutical Trade Fair showcased Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., highlighting its brand, high-value product matrix, and ecological win-win philosophy [3][4] Group 1: Product Showcase - Zhenbaodao Pharmaceutical exhibited high-quality product lines focusing on cardiovascular, respiratory, and anti-infection treatment areas, including key products like Injection Blood Setong 100mg and Xuechuang Capsule [3] - The company has developed a dual-driven system of "Traditional Chinese Medicine + Chemical Medicine," featuring products such as Compound Qilan Oral Liquid and Injection Ammonium Bromide [3] Group 2: Marketing Strategy - The company emphasized its 2025 "Guangshen Tuo" marketing strategy, which segments regional markets based on product attributes and promotes a model of "recruiting merchants, finding merchants, and servicing merchants" to enhance terminal coverage and sales efficiency [4] - Zhenbaodao Pharmaceutical established a three-tier academic promotion system, integrating medical, market, and data teams to monitor industry trends and provide precise marketing strategies [4] Group 3: Collaborative Ecosystem - The participation in the trade fair demonstrated the company's competitive product pipeline and industrial layout, aiming to build a comprehensive ecosystem of strategic collaboration, resource sharing, and value co-creation [4] - The company plans to continue driving innovation and collaboration, positioning itself to lead the pharmaceutical industry towards higher value creation [4]